This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Inflammation	Phosphoinositide 3-kinase- β (PI3K β); PI3K δ	<p>Rat studies identified a pyrrolo pyridine analog as a dual inhibitor of PI3Kβ and PI3Kδ that could help treat inflammation. In a rat model of collagen-induced arthritis, the dual inhibitor decreased hind-paw inflammation and cartilage erosion compared with vehicle. Next steps were undisclosed but could include evaluating the lead dual inhibitor in additional animal models of inflammation.</p> <p>AMG 319, a small molecule inhibitor of PI3Kδ from Amgen Inc., is in Phase I testing to treat hematological malignancies.</p> <p>GS 1101, a small molecule inhibitor of PI3Kδ from Gilead Sciences Inc., is in Phase III testing to treat chronic lymphocytic leukemia (CLL) and Phase II testing to treat non-Hodgkin's lymphoma (NHL).</p> <p>At least six other companies have inhibitors of PI3Kδ in Phase II testing or earlier to treat cancer, autoimmune diseases or inflammatory conditions.</p> <p>SciBX 5(35); doi:10.1038/scibx.2012.929 Published online Sept. 6, 2012</p>	Patent application filed; licensing status undisclosed	<p>Gonzalez-Lopez de Turiso, F. <i>et al.</i> <i>J. Med. Chem.</i>; published online Aug. 9, 2012; doi:10.1021/jm300679u</p> <p>Contact: Felix Gonzalez-Lopez de Turiso, Amgen Inc., South San Francisco, Calif. e-mail: felgonza@amgen.com</p>